ATE477803T1 - Metabolit von quetiapine - Google Patents

Metabolit von quetiapine

Info

Publication number
ATE477803T1
ATE477803T1 AT04743131T AT04743131T ATE477803T1 AT E477803 T1 ATE477803 T1 AT E477803T1 AT 04743131 T AT04743131 T AT 04743131T AT 04743131 T AT04743131 T AT 04743131T AT E477803 T1 ATE477803 T1 AT E477803T1
Authority
AT
Austria
Prior art keywords
quetiapine
metabolite
Prior art date
Application number
AT04743131T
Other languages
English (en)
Inventor
Scott Grimm
Helen Winter
Patricia C Davis
Raymond F Suckow
Jeffrey Goldstein
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE477803T1 publication Critical patent/ATE477803T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04743131T 2003-07-02 2004-06-28 Metabolit von quetiapine ATE477803T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
PCT/GB2004/002783 WO2005002586A1 (en) 2003-07-02 2004-06-28 Metabolite of quetiapine

Publications (1)

Publication Number Publication Date
ATE477803T1 true ATE477803T1 (de) 2010-09-15

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743131T ATE477803T1 (de) 2003-07-02 2004-06-28 Metabolit von quetiapine

Country Status (20)

Country Link
US (1) US20050026900A1 (de)
EP (1) EP1644005B1 (de)
JP (1) JP2007516193A (de)
KR (1) KR20060082037A (de)
CN (1) CN1816339B (de)
AR (1) AR045004A1 (de)
AT (1) ATE477803T1 (de)
AU (1) AU2004253334A1 (de)
BR (1) BRPI0412127A (de)
CA (1) CA2531284A1 (de)
DE (1) DE602004028739D1 (de)
ES (1) ES2349091T3 (de)
IL (1) IL172616A0 (de)
IS (1) IS8283A (de)
MX (1) MXPA05013869A (de)
NO (1) NO20060556L (de)
RU (1) RU2005141060A (de)
TW (1) TW200509944A (de)
UY (1) UY28400A1 (de)
WO (1) WO2005002586A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
NZ547911A (en) 2003-12-22 2010-06-25 Acadia Pharm Inc Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
EP1838325A1 (de) * 2005-01-07 2007-10-03 AstraZeneca AB Neue verwendung von piperazin-1-yldibenzo [b,f][1,4]thiazepin oder seines pharmazeutisch annehmbaren salzes und orale pharmazeutische zusammensetzungen
EP1865962A2 (de) * 2005-04-04 2007-12-19 Arcadia Pharmaceuticals Inc. Verwendung von n-desmethylclozapin und verwandten verbindungen als dopaminstabilisierende mittel
EP1869007A1 (de) * 2005-04-14 2007-12-26 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von quetiapinfumaraten
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
JP2009516707A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 固形製剤
WO2007062339A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Liquid formulations
CN101360502B (zh) * 2005-11-18 2012-03-14 阿斯利康公司 结晶形式
WO2008116144A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Methods of treating mood disorders
CN101360724A (zh) * 2005-11-18 2009-02-04 阿斯利康公司 盐形式
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010531292A (ja) * 2006-12-20 2010-09-24 アストラゼネカ・アクチエボラーグ 化合物及びその使用
EP2120957A4 (de) * 2006-12-20 2011-05-04 Astrazeneca Ab Verbindungen und ihre verwendungen
EP2120563A4 (de) * 2006-12-20 2011-04-27 Astrazeneca Ab Verbindungen und ihre verwendungen
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US20110223207A1 (en) 2010-03-11 2011-09-15 Travis Mickle Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用

Also Published As

Publication number Publication date
AU2004253334A1 (en) 2005-01-13
JP2007516193A (ja) 2007-06-21
UY28400A1 (es) 2005-01-31
DE602004028739D1 (de) 2010-09-30
NO20060556L (no) 2006-04-03
CN1816339B (zh) 2010-12-15
WO2005002586A8 (en) 2006-02-09
RU2005141060A (ru) 2006-07-27
EP1644005B1 (de) 2010-08-18
ES2349091T3 (es) 2010-12-27
IS8283A (is) 2006-02-01
BRPI0412127A (pt) 2006-08-15
WO2005002586A1 (en) 2005-01-13
CN1816339A (zh) 2006-08-09
IL172616A0 (en) 2006-04-10
MXPA05013869A (es) 2006-02-28
CA2531284A1 (en) 2005-01-13
KR20060082037A (ko) 2006-07-14
TW200509944A (en) 2005-03-16
AR045004A1 (es) 2005-10-12
US20050026900A1 (en) 2005-02-03
EP1644005A1 (de) 2006-04-12

Similar Documents

Publication Publication Date Title
ATE477803T1 (de) Metabolit von quetiapine
EP1642377A4 (de) Vibrationseinrichtung
ITMI20041123A1 (it) Fissaggio
DE60309013D1 (de) Knoten
NO20043696L (no) Gamma-sekretaseinhibitorer
DK1472255T3 (da) Aza-arylpiperaziner
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
EP1560914A4 (de) Grasendophyten
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DE602004024640D1 (de) Reinigung von titantetrachlorid
ITMI20021327A1 (it) Nuove ossialchilpiperazine
ATE410417T1 (de) Kristallmodifikationen von triazinylaminostilbenen
ITMS20020001U1 (it) Help your self
UA9821S (uk) Комплект етикеток
UA7807S (uk) Комплект етикеток
UA8496S (uk) Комплект етикеток
UA9242S (uk) Комплект етикеток
UA9239S (uk) Комплект етикеток
UA8155S (uk) Комплект етикеток
UA7418S (uk) Комплект етикеток
UA8270S (uk) Комплект етикеток
UA8904S (uk) Комплект етикеток
UA6746S (uk) Кобза чотириструнна
FIU20020171U0 (fi) Puupalkki
SE0202366D0 (sv) Hjälpmedel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties